Raman-based Analysis of Dispersed Versus Aggregated Drug Particles in MDI Formulations for Chemically-specific Sizing and Polymorphic Purity Assessment

Share Button

Raman-based analysis of dispersed versus aggregated drug particlesPresented at: Drug Delivery to the Lung 24,  2013
 O Olkhovyk1,  R Price 2 and J Shur 2
1. Gateway Analytical,  5316 William Flynn Highway, Gibsonia, PA 15044
2. University of Bath, Bath, BA2 7AY, UK
Release Date: Thurs., Dec 12, 2013

In this study, Raman Chemical Imaging (RCI) was used to investigate the active pharmaceutical ingredients (API) particle size distribution (PSD) and degree of drug particle aggregation in a commercial MDI, Flixotide, which contains an anti-inflammatory corticosteroid (fluticasone propionate). Assessment of free-standing API particles and aggregated API particles was done by visual inspection of Raman-identified API particles as it relates to the spatial location of all detected fluticasone particles on a the brightfield and Raman Chemical fusion Images.

By using RCI it is possible also to identify presence of foreign particulates in the formulations and obtain spectrally and spatially resolved images of each particle for accurate particle size determination and recognition of aggregated versus stand-alone particles. RCI can easily separate different chemical species or polymorphic/hydrate forms of the same chemical within single particle or aggregate for identification of polymorphic impurity/unwanted phase transition of the drug.



Dr. Oksana Olkhovyk Ph.D., plays an important role supporting analytical testing services as the Senior Scientist at Gateway Analytical. She has over 15 years experience in Raman spectroscopy, imaging and material characterization. Dr. Olkhovyk has worked to support hundreds of projects as a scientific liaison between Gateway Analytical and their customers, as well as academic and industrial collaborators.

Leave a Reply